The M2BPGi level before DAA treatment and the AFP level after DAA treatment differed significantly between HCC naïve patients that developed HCC and those that did not (p < 0.05) (Table 5 and Table S1). This evidence concerns the gene AFP and hepatocellular carcinoma.